There is currently considerable interest in understanding the mechanisms of action of pyrazinamide (PZA), a critical frontline tuberculosis (TB) drug that plays a unique role in shortening TB therapy due to its unique activity against Mycobacterium tuberculosis persisters that are not killed by other TB drugs. 1, 2 Despite the importance of PZA in the treatment of both drug susceptible and drug-resistant TB and its simple structure, its mechanisms of action are complex and are not well understood. 1,2 PZA is a prodrug that is converted to the active form pyrazinoic acid (POA) by nicotinamidase/pyrazinamidase (PZase) encoded by the pncA gene, 3 whose mutation is the most common mechanism of PZA resistance in M. tuberculosis. [3] [4] [5] However, some low level PZA-resistant strains (MIC=200-300 µg/ml, pH6.0) do not have mutations in the pncA gene. 5, 6 Recent studies have identified rpsA, which encodes the ribosomal protein S1 involved in both translation and trans-translation process, as a target of PZA, 7 where its mutations are associated with PZA resistance from clinical isolates. In addition, mutations in panD encoding aspartate decarboxylase were identified as a new mechanism of PZA resistance from in vitro mutants resistant to PZA and the PanD protein was found to be another target of PZA. 8,9 panD mutations were initially found in mutants resistant to PZA 8 and then in mutants resistant to POA. 9,10 It is worth noting that previously POA-resistant mutants could not be isolated at acid pH which is required for higher activity of PZA against M. tuberculosis.
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However, we were able to successfully isolate POA-resistant mutants with high POA concentrations at close to neutral pH (pH 6.8), 9 which led to discovery of new genes involved in POA and PZA resistance. For example, clpC1, which was also isolated from mutants resistant to PZA, 11 was identified in mutants resistant to POA. 12 3 However, in our previous study, only a small number of 30 POA-resistant mutants of M.
tuberculosis were analyzed, where all the mutations were mapped to the panD gene. 9 Since some PZA-resistant strains such as strain 9739 5 derived from our previous study. 9 Briefly, the genomic DNA from the 109 POA-resistant mutants was extracted and subjected to PCR DNA sequencing of the known genes pncA, rpsA, panD, clpC1 involved in PZA resistance. It is noteworthy that 101/109 (93%) of POA-resistant mutants had panD mutations, with 75 of the panD mutants having the same dominant M117I mutation as previsouly identified. 9 However, 8 POA-resistant mutants did not have panD mutations, and 4 of the mutants had the same mutation in clpC1 where A271G nucleotide change caused amino acid substitution S91G. It is noteworthy that the clpC1 mutation S91G is different from our previsouly identified mutation (G99D) 11 and those by Gopal et al.. 12 However, the remaining 4 POA-resistant mutants were also resistant to PZA, which are 2-4 fold more resistant (50-100 µg/ml PZA, pH5.8) than parent strain M. tuberculosis H37Ra (25 µg/ml PZA, pH5.8); but these 4 POA-resistant mutants did not have any mutations in the known PZA resistance genes pncA, rpsA, panD, or clpC1. Whole genome sequencing of the 4 POA-resistant mutants was performed as we described previously, 8 and sequence analysis revealed that they all had the same two mutations rv1411c (Lipoprotein LprG C672T change leading to W224STOP) and rv0521 (Methyltransferase, C295T causing amino acid substitution R99W) ( Table 1) . Sanger sequencing of the PCR products confirmed the mutations identified by the whole genome 4 sequencing. However, Strain 3G1 had only the two identical mutations in LprG (rv1411c) and rv0521 while the remaining 3 mutants had additional low percentage of heterogeneous mutations in rv3630 (hypothetical protein), rv0010c (hypothetical protein), ppsC (phenolpthiocerol synthesis type-I polyketide synthase C) and cyp128 (cytochrome P450 128) ( Table 1) . Strain 3H4 had a point mutation T199C, causing amino acid change T67A in cytochrome P450 128 (cyp128, Rv2268c), which encodes a heme-thiolate monooxygenase.
LprG-Rv1410 has been shown to participate in triacylglyceride (TAG) transport in M.
tuberculosis as loss of its function leads to intracellular TAG accumulation, and is critical for regulating bacterial growth and metabolism during carbon starvation and infection in mice. 13 The finding that all 4 POA-resistant mutants have the same W224Stop mutation in LprG suggests that the non-functional LprG will lead to higher TAG accumulation and thus causing higher metabolism, which is known to be a condition that antagonizes PZA/POA activity. 2 However, the contribution of the low abundance mutations in rv3630 (hypothetical protein), 5 rv0010c (hypothetical protein), ppsC (phenolpthiocerol synthesis type-I polyketide synthase C) and cyp128 (cytochrome P450 128) ( Table 1) is less clear. Previous studies have found mutations in ppsA-E locus involved in synthesis of virulence factor phthiocerol dimycocerosate (PDIM) are associated with PZA resistance, 10 but the role of the pps operon gene mutations including ppsC mutations in PZA resistance remains to be determined. In M. tuberculosis, cytochrome P450 proteins have many functions such as virulence, persistence, cholesterol metabolism, lipid degradation, regulator, resistance to azole drugs. 14 abundance gene mutations cannot be ruled out, it is likely that these mutations may serve to elevate resistance levels or allow the mutant to adapt to the two mutations in LprG and methyltransferase. These possibilities remain to be tested in future studies.
Despite the complexity of the mode of action of PZA, significant progress has been made in recent years in our understanding of this peculiar and yet critical drug, as PZA has been shown to interfere with multiple targets including trans-translation (RpsA), energy production (PanD), 
